United Therapeutics pays $800M-plus to grab Arena’s PhIII PAH drug via @endpts

United Ther­a­peu­tics $UTHR is pay­ing an $800 mil­lion cash up­front in a big bet to stay among the lead­ers in pul­monary ar­te­r­ial hy­per­ten­sion, grab­bing rights to Arena Phar­ma­ceu­ti­cals’ ra­linepag in the deal. And the ex­ec­u­tive crew is will­ing to add hun­dreds of mil­lions more in mile­stones if they can stay on track through to an ap­proval and com­mer­cial­iza­tion.

Source: United Therapeutics pays $800M-plus to grab Arena’s PhIII PAH drug – Endpoints News